Can Ketamine Be Considered After Traditional Antidepressants Have Not Worked?

If you have taken two, three, or four different antidepressants and still feel the weight of depression, you have likely been told some version of the same thing each time: let’s try another one. A new prescription. Another six to eight weeks of waiting. Another round of side effects to absorb while you hope this is the one that finally works.

That cycle is exhausting. It is also more common than most people realize — and it is not a personal failure.

Antidepressants help many people, but remission is not guaranteed and the probability of remission generally decreases across successive treatment steps. The STAR*D study remains an important illustration of that problem, although the exact cumulative remission rate depends on how the data are analyzed. The practical point is not a single percentage: a clinically meaningful group of patients continue to have depressive symptoms after multiple adequate treatments.

When depression persists after adequate treatment, clinicians reassess the diagnosis, adherence, dose and duration, co-occurring conditions, and alternative treatment strategies rather than assuming the next step should simply be another medication from the same class.

For some patients, that reassessment includes treatments with different mechanisms, such as ketamine or esketamine. Whether either is appropriate depends on diagnosis, treatment history, medical risk, substance-use history, current medications, route, and the treatment setting.

A note on route and formulation. Ketamine evidence is route-specific. Much of the controlled antidepressant literature uses intravenous racemic ketamine, while FDA-approved intranasal esketamine (Spravato®) has its own trial program and REMS requirements. Some real-world telehealth studies involve sublingual ketamine. Current Vantage materials describe clinician-guided compounded racemic ketamine nasal spray. That compounded nasal formulation is not FDA-approved for any psychiatric condition, and route-matched controlled evidence is limited. Results from IV, sublingual, or esketamine studies should not be presented as expected outcomes for compounded nasal ketamine.

What “Treatment-Resistant Depression” Actually Means

Treatment-resistant depression (TRD) is commonly defined in research and clinical practice as major depressive disorder that has not responded adequately to at least two antidepressant treatments given at appropriate dose and duration. Definitions vary somewhat across studies and health systems, so candidacy should be determined from the full treatment history rather than a medication count alone.

Two qualifiers in that definition matter enormously, and they are the first thing a careful provider will examine:

Adequate treatment. A clinician considers whether prior medications were taken at a therapeutic dose for an adequate period and whether side effects, adherence, or early discontinuation limited the trial. There is no single duration that fits every medication and patient.

Before labeling depression as treatment-resistant, clinicians may also reassess for bipolar-spectrum illness, substance use, sleep disorders, thyroid or other medical contributors, medication effects, chronic pain, trauma, and major life circumstances. This does not mean symptoms are “all situational”; it means treatment selection depends on getting the diagnosis and context as accurate as possible.

That said — when the trials were real, the doses were adequate, the diagnosis holds, and the depression persists, you have arrived at a legitimate clinical crossroads. This is precisely the population in which ketamine and esketamine have been studied.

How Ketamine Differs From SSRIs and SNRIs

The most important thing to understand about ketamine is that it does not work the way conventional antidepressants work. This is not a marketing distinction. It is a different pharmacological target.

SSRIs and SNRIs primarily modify monoamine signaling, while ketamine acts on glutamatergic signaling through NMDA-receptor antagonism and downstream pathways. The exact antidepressant mechanism of ketamine is still being studied and is more complex than a single receptor or “rewiring” event.

A leading mechanistic model involves NMDA-receptor blockade, increased AMPA signaling, and downstream effects on BDNF, mTORC1, and synaptic plasticity. Much of the detailed synaptogenesis evidence comes from animal and cellular studies; human research supports rapid changes in glutamatergic and network function but does not establish one complete mechanism.

Clinically, IV ketamine and esketamine can reduce depressive symptoms more rapidly than conventional antidepressants in some patients, often within a day or several days in trials. That rapid effect has not been established to the same degree for every route or compounded formulation.

For patients who have not improved after multiple standard treatments, a different mechanism can be clinically relevant. It does not mean ketamine will work, and it does not make another evidence-based antidepressant or augmentation strategy inappropriate.

What the Evidence Shows in Treatment-Resistant Patients

The evidence base here is substantial and has matured considerably.

A 2022 systematic review and meta-analysis of 79 real-world studies involving 2,665 patients with treatment-resistant depression reported an average response rate of about 45% and remission rate of about 30%. The included studies varied in route, dosing, design, and clinical setting, so these pooled figures are useful context but are not route-specific predictions for compounded intranasal ketamine.

Read those numbers both ways. The pooled data show meaningful improvement for many patients, and they also show that most patients did not reach remission. Ketamine is an option with evidence; it is not a certainty.

Esketamine (Spravato®), the S-enantiomer of ketamine, is FDA-approved for treatment-resistant depression in adults and since 2025 may be used for TRD as monotherapy or with an oral antidepressant. It remains subject to the Spravato REMS and must be administered in a certified healthcare setting with required monitoring. That approval does not apply to compounded racemic ketamine nasal spray.

Racemic ketamine is FDA-approved as an anesthetic and is used off-label for psychiatric conditions. Off-label prescribing can be appropriate when a licensed clinician judges the evidence and patient-specific circumstances to support it, but it is different from an FDA-approved psychiatric indication. Compounded ketamine products are not FDA-approved or evaluated by FDA before marketing for safety, effectiveness, or quality.

Can You Take Ketamine and an Antidepressant Together?

Many patients receiving ketamine or esketamine continue other psychiatric medications, but the full regimen should be reviewed by the prescribing clinician. Drug interactions, sedation, blood pressure, substance-use risk, and the reason each medication is being used all matter.

Ketamine does not have the same serotonergic mechanism as SSRIs or SNRIs, but that does not make every combination automatically safe or beneficial. Medication decisions should be individualized.

Benzodiazepines, lamotrigine, stimulants, blood-pressure medications, sedatives, alcohol and other substances may be relevant to dosing or safety, and the literature on some pharmacodynamic interactions is mixed. Uncontrolled hypertension, significant cardiovascular disease, psychosis, mania, pregnancy, and substance-use history are among the factors clinicians may evaluate before prescribing.

Never stop, start, or adjust a psychiatric medication on your own in order to prepare for ketamine treatment. Discontinuation of an antidepressant without a taper can cause significant withdrawal symptoms and relapse. This is a conversation to have with a prescriber, not a decision to make in advance of one.

How Quickly Does It Work — and How Long Does It Last?

Rapid antidepressant effects are well documented for IV ketamine and esketamine in selected depressed populations. Some participants improve within 24 hours, while others improve later or not at all. The same timeline should not be assumed for compounded intranasal racemic ketamine without route-specific evidence.

Durability varies. After a single IV dose, benefit often diminishes over days to weeks, and approved esketamine uses induction and maintenance schedules. Racemic ketamine protocols vary substantially by route and practice. There is no single evidence-based maintenance schedule that can be applied to every formulation or patient.

Ketamine is not a cure. Supportive psychotherapy, behavioral work, and follow-up may be clinically valuable, but evidence has not established that “integration” or psychotherapy reliably amplifies or prolongs ketamine’s antidepressant effect. A 2026 systematic review found that controlled studies had not demonstrated clear added benefit of psychotherapy over ketamine alone. Support should therefore be offered for patient care and coping without promising synergy.

Is Ketamine Therapy Right for You?

No article can determine candidacy. A clinician reviews diagnosis, prior treatments, current medications, cardiovascular status, substance-use history, psychosis or mania history, pregnancy status, home environment, ability to follow safety instructions, and whether the proposed route and setting are appropriate.

If you are having thoughts of suicide or self-harm, please do not wait for an appointment. Call or text the 988 Suicide and Crisis Lifeline now. Ketamine has shown rapid effects on suicidal ideation in research settings, but acute suicidality is an emergency that requires immediate human support, not a scheduled telehealth visit.

For everyone else carrying the specific fatigue of having tried and tried again: the fact that standard treatment has not worked does not mean nothing will. It means the next step should be a different one.

Vantage Telehealth is a technology platform that connects users with independent licensed clinicians through Impact Health USA. Current Vantage materials describe a clinician-guided model using compounded racemic ketamine nasal spray. The treating clinician determines eligibility, whether an in-person evaluation is required, the prescription and monitoring plan, and whether a different treatment or level of care is more appropriate.

Learn more about ketamine therapy at Vantage

Frequently Asked Questions

Can ketamine therapy help patients who have failed multiple antidepressants?

Ketamine and esketamine can help some patients with treatment-resistant depression. A 2022 meta-analysis of 79 real-world ketamine studies reported about 45% response and 30% remission on average, but the studies used different routes and protocols. These figures do not predict response to compounded intranasal racemic ketamine, and candidacy requires individualized evaluation.

How many antidepressant failures qualify someone for ketamine therapy?

Treatment-resistant depression is commonly defined as major depressive disorder that has not responded adequately to at least two antidepressant treatments of adequate dose and duration, although definitions vary. A clinician reviews the quality of prior trials, adherence, diagnosis, co-occurring conditions, and other treatment options before determining whether ketamine or esketamine should be considered.

How does ketamine’s mechanism differ from SSRIs and SNRIs?

SSRIs and SNRIs primarily affect monoamine signaling. Ketamine acts on glutamatergic signaling through NMDA-receptor antagonism and downstream pathways involving AMPA signaling and neuroplasticity. The detailed mechanism is still being studied, and much of the synaptic-pathway evidence comes from preclinical research.

How quickly does ketamine relieve depression symptoms compared to antidepressants?

Rapid symptom improvement within a day or several days is well documented for IV ketamine and FDA-approved esketamine in selected depressed populations. Response varies, and the same timing should not be assumed for every route or compounded formulation. Conventional antidepressants generally require longer trials before their full effect can be assessed.

Can ketamine be used alongside an existing antidepressant?

Ketamine or esketamine may be used while a patient continues other psychiatric medications, but the regimen must be reviewed by the prescriber. Potential interactions, sedation, blood pressure, substance use, and the role of each medication matter. Never start, stop, or change psychiatric medication solely to prepare for ketamine without clinician guidance.

What is the success rate of ketamine for treatment-resistant depression?

A 2022 meta-analysis of real-world ketamine studies reported about 45% response and 30% remission across varied routes and protocols. FDA-approved esketamine has separate trial data. These are group averages, not a “success rate” for a particular compounded product or individual patient, and a substantial share of patients do not respond.

Selected References

• Alnefeesi Y, et al. Real-world effectiveness of ketamine in treatment-resistant depression: systematic review and meta-analysis. Journal of Psychiatric Research. 2022.

• FDA. Spravato (esketamine) Prescribing Information, 2025 label update.

• FDA. Potential risks associated with compounded ketamine products for psychiatric disorders. Compounding Risk Alert. 2023.

• FDA. Potential risks associated with compounded ketamine nasal spray. Compounding Risk Alert. 2022.

See how Vantage Telehealth can help — Get Started →

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, treatment, or a recommendation that ketamine is appropriate for any individual. Ketamine is a Schedule III controlled substance. Racemic ketamine is FDA-approved as an anesthetic, not for any psychiatric condition; psychiatric use is off-label. Compounded ketamine products, including compounded racemic ketamine nasal spray, are not FDA-approved or evaluated by FDA for safety, effectiveness, quality, or any psychiatric indication. Spravato® (esketamine) is a distinct FDA-approved product with specific depression-related indications and REMS requirements. Evidence, safety, dosing, and monitoring differ by route and formulation. Federal telemedicine rules for controlled-substance prescribing are time-sensitive and state law may impose additional requirements, including an in-person evaluation. Vantage Telehealth is not a medical provider; it is a technology platform that connects users with independent licensed clinicians through Impact Health USA. All prescribing and clinical decisions are made solely by the treating clinician. Vantage is not an emergency service. For a mental-health crisis or thoughts of suicide or self-harm, call or text 988. For an immediate life-threatening emergency, call 911.